Histology to 3D in vivo MR registration for volumetric evaluation of MRgFUS treatment assessment biomarkers

Abstract Advances in imaging and early cancer detection have increased interest in magnetic resonance (MR) guided focused ultrasound (MRgFUS) technologies for cancer treatment. MRgFUS ablation treatments could reduce surgical risks, preserve organ tissue and function, and improve patient quality of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Blake E. Zimmerman, Sara L. Johnson, Henrik A. Odéen, Jill E. Shea, Rachel E. Factor, Sarang C. Joshi, Allison H. Payne
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4726c0e6eea74e15a2541244e93016df
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4726c0e6eea74e15a2541244e93016df
record_format	dspace
spelling	oai:doaj.org-article:4726c0e6eea74e15a2541244e93016df2021-12-02T18:48:01ZHistology to 3D in vivo MR registration for volumetric evaluation of MRgFUS treatment assessment biomarkers10.1038/s41598-021-97309-02045-2322https://doaj.org/article/4726c0e6eea74e15a2541244e93016df2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97309-0https://doaj.org/toc/2045-2322Abstract Advances in imaging and early cancer detection have increased interest in magnetic resonance (MR) guided focused ultrasound (MRgFUS) technologies for cancer treatment. MRgFUS ablation treatments could reduce surgical risks, preserve organ tissue and function, and improve patient quality of life. However, surgical resection and histological analysis remain the gold standard to assess cancer treatment response. For non-invasive ablation therapies such as MRgFUS, the treatment response must be determined through MR imaging biomarkers. However, current MR biomarkers are inconclusive and have not been rigorously evaluated against histology via accurate registration. Existing registration methods rely on anatomical features to directly register in vivo MR and histology. For MRgFUS applications in anatomies such as liver, kidney, or breast, anatomical features that are not caused by the treatment are often insufficient to drive direct registration. We present a novel MR to histology registration workflow that utilizes intermediate imaging and does not rely on anatomical MR features being visible in histology. The presented workflow yields an overall registration accuracy of 1.00 ± 0.13 mm. The developed registration pipeline is used to evaluate a common MRgFUS treatment assessment biomarker against histology. Evaluating MR biomarkers against histology using this registration pipeline will facilitate validating novel MRgFUS biomarkers to improve treatment assessment without surgical intervention. While the presented registration technique has been evaluated in a MRgFUS ablation treatment model, this technique could be potentially applied in any tissue to evaluate a variety of therapeutic options.Blake E. ZimmermanSara L. JohnsonHenrik A. OdéenJill E. SheaRachel E. FactorSarang C. JoshiAllison H. PayneNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Blake E. Zimmerman Sara L. Johnson Henrik A. Odéen Jill E. Shea Rachel E. Factor Sarang C. Joshi Allison H. Payne Histology to 3D in vivo MR registration for volumetric evaluation of MRgFUS treatment assessment biomarkers
description	Abstract Advances in imaging and early cancer detection have increased interest in magnetic resonance (MR) guided focused ultrasound (MRgFUS) technologies for cancer treatment. MRgFUS ablation treatments could reduce surgical risks, preserve organ tissue and function, and improve patient quality of life. However, surgical resection and histological analysis remain the gold standard to assess cancer treatment response. For non-invasive ablation therapies such as MRgFUS, the treatment response must be determined through MR imaging biomarkers. However, current MR biomarkers are inconclusive and have not been rigorously evaluated against histology via accurate registration. Existing registration methods rely on anatomical features to directly register in vivo MR and histology. For MRgFUS applications in anatomies such as liver, kidney, or breast, anatomical features that are not caused by the treatment are often insufficient to drive direct registration. We present a novel MR to histology registration workflow that utilizes intermediate imaging and does not rely on anatomical MR features being visible in histology. The presented workflow yields an overall registration accuracy of 1.00 ± 0.13 mm. The developed registration pipeline is used to evaluate a common MRgFUS treatment assessment biomarker against histology. Evaluating MR biomarkers against histology using this registration pipeline will facilitate validating novel MRgFUS biomarkers to improve treatment assessment without surgical intervention. While the presented registration technique has been evaluated in a MRgFUS ablation treatment model, this technique could be potentially applied in any tissue to evaluate a variety of therapeutic options.
format	article
author	Blake E. Zimmerman Sara L. Johnson Henrik A. Odéen Jill E. Shea Rachel E. Factor Sarang C. Joshi Allison H. Payne
author_facet	Blake E. Zimmerman Sara L. Johnson Henrik A. Odéen Jill E. Shea Rachel E. Factor Sarang C. Joshi Allison H. Payne
author_sort	Blake E. Zimmerman
title	Histology to 3D in vivo MR registration for volumetric evaluation of MRgFUS treatment assessment biomarkers
title_short	Histology to 3D in vivo MR registration for volumetric evaluation of MRgFUS treatment assessment biomarkers
title_full	Histology to 3D in vivo MR registration for volumetric evaluation of MRgFUS treatment assessment biomarkers
title_fullStr	Histology to 3D in vivo MR registration for volumetric evaluation of MRgFUS treatment assessment biomarkers
title_full_unstemmed	Histology to 3D in vivo MR registration for volumetric evaluation of MRgFUS treatment assessment biomarkers
title_sort	histology to 3d in vivo mr registration for volumetric evaluation of mrgfus treatment assessment biomarkers
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/4726c0e6eea74e15a2541244e93016df
work_keys_str_mv	AT blakeezimmerman histologyto3dinvivomrregistrationforvolumetricevaluationofmrgfustreatmentassessmentbiomarkers AT saraljohnson histologyto3dinvivomrregistrationforvolumetricevaluationofmrgfustreatmentassessmentbiomarkers AT henrikaodeen histologyto3dinvivomrregistrationforvolumetricevaluationofmrgfustreatmentassessmentbiomarkers AT jilleshea histologyto3dinvivomrregistrationforvolumetricevaluationofmrgfustreatmentassessmentbiomarkers AT rachelefactor histologyto3dinvivomrregistrationforvolumetricevaluationofmrgfustreatmentassessmentbiomarkers AT sarangcjoshi histologyto3dinvivomrregistrationforvolumetricevaluationofmrgfustreatmentassessmentbiomarkers AT allisonhpayne histologyto3dinvivomrregistrationforvolumetricevaluationofmrgfustreatmentassessmentbiomarkers
_version_	1718377618656460800

Histology to 3D in vivo MR registration for volumetric evaluation of MRgFUS treatment assessment biomarkers

Ejemplares similares